ENTYVIO (vedolizumab) Patient Assistance Program
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey.
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Entyvio (vedolizumab) is FDA-approved for moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD) in adults. It is an integrin α4β7 antagonist — uniquely gut-selective among IBD biologics. Available as IV infusion (induction and maintenance) and SC injection (maintenance).
- Without assistance, Entyvio costs commonly run approximately $5,500–$6,500 per IV infusion (every 8 weeks after induction) or per month of SC maintenance.
- Through AffordMyPrescriptions, qualifying patients can access Entyvio for a flat $69.95 per month — our advocacy team manages the entire enrollment, refills, and renewal process.
- There is no biosimilar of Entyvio in the U.S. as of 2026. Other IBD biologics include TNF inhibitors (Humira/biosimilars, Remicade/biosimilars, Cimzia, Simponi), IL-12/23 inhibitors (Stelara, with biosimilars; Skyrizi for Crohn's), IL-23 inhibitors (Omvoh for UC and CD), and JAK inhibitors (Xeljanz, Rinvoq for UC).
What Is Entyvio Prescription Assistance Program?
The Entyvio Prescription Assistance Program is a manufacturer-sponsored initiative that provides Entyvio at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for IBD patients who are uninsured or underinsured, as well as Medicare Part D beneficiaries.
Navigating the program on your own means dealing with eligibility verification, gastroenterology coordination, prior-authorization documentation, infusion-center or specialty pharmacy logistics, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing infusion or refill coordination and annual re-certification.
Pharmacy Price Comparison
- Without assistance, Entyvio costs roughly $5,500–$6,500 per dose. A Patient Assistance Program is the meaningful path forward — if you qualify:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$6,300/dose | Save ~$6,230/dose |
| CVS Pharmacy | ~$6,500/dose | Save ~$6,430/dose |
| Walmart | ~$5,700/dose | Save ~$5,630/dose |
| Costco | ~$5,600/dose | Save ~$5,530/dose |
Specialty Pharmacy | ~$5,800/dose | Save ~$5,730/dose |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Entyvio Prescription Program?
The Patient Assistance Program is free to apply for and provides Entyvio at no medication cost if approved. Our $69.95/month service covers full advocacy.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Entyvio:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
- Coupon cards expire and require constant renewal
Still $5,500–$6,500/dose per month even with the best discoun
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly through the assistance program
- We manage all paperwork, refills, and annual renewals
- If denied, we explore alternative savings on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Entyvio assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Entyvio Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Understanding Entyvio:
Entyvio (vedolizumab) is a humanized monoclonal antibody that selectively blocks integrin α4β7 — a gut-specific adhesion molecule. By blocking α4β7, vedolizumab prevents gut-homing T-cells from migrating into the inflamed intestinal mucosa, while leaving systemic immune function largely intact. This gut-selectivity is the key advantage of Entyvio over systemically-acting biologics.
How Entyvio Works:
Inflammatory bowel disease (UC and CD) is driven by T-cells expressing the $\alpha_4\beta_7$ integrin migrating from the blood into the intestinal mucosa by binding to MAdCAM-1. Vedolizumab (Entyvio) is a monoclonal antibody that binds to $\alpha_4\beta_7$, blocking this specific interaction and preventing these gut-homing lymphocytes from entering the intestinal tissue. This targeted action reduces intestinal inflammation while leaving lymphocyte trafficking to other organs unaffected. Because its effects are largely restricted to the gut, the medication provides a favorable safety profile with lower systemic infection risks and no PML risk.
Form and use:
Entyvio can be administered as an intravenous (IV) infusion or a subcutaneous (SC) injection depending on the treatment phase. The IV formulation is given as a 300 mg infusion over 30 minutes at weeks 0, 2, and 6 for induction, followed by maintenance infusions every 8 weeks. Alternatively, patients can transition to a maintenance dose of 108 mg via subcutaneous injection every 2 weeks after completing their initial IV induction. The SC formulation is designed for self-administration, allowing patients to conveniently dose themselves at home.
Generic availability:
As of 2026, there is no biosimilar version of Entyvio available in the United States. Other biologic options for treating IBD include TNF inhibitors like Humira and Remicade (both with available biosimilars), Cimzia, and Simponi. Additional alternatives encompass IL-12/23 inhibitors like Stelara (which has biosimilars like Selarsdi, Pyzchiva, and Wezlana) and Skyrizi, alongside IL-23 inhibitors like Omvoh and Tremfya. Patients also have access to oral JAK inhibitors, including Rinvoq and Xeljanz, the latter of which has a generic version available.
Warnings:
Entyvio carries warnings for infusion-related and hypersensitivity reactions, including rare instances of anaphylaxis. There is a risk of serious infections, such as sepsis and opportunistic infections, though this risk is lower than with systemic biologics due to the drug’s gut-selectivity. Patients must undergo screening for tuberculosis reactivation before treatment, and liver function tests (LFTs) should be monitored due to potential hepatotoxicity. Finally, live vaccines should be avoided during treatment, and progressive multifocal leukoencephalopathy (PML) remains a theoretical though unobserved risk.
FAQ (Frequently Asked Questions)
How Much Does Entyvio Cost Without Insurance?
Entyvio costs approximately $5,500–$6,500 per IV infusion (every 8 weeks after induction) or per month of SC maintenance. Through AffordMyPrescriptions, qualifying patients receive Entyvio at no medication cost — our $69.95 monthly fee covers full advocacy and program management.
What Does 'Gut-Selective' Mean?
Most IBD biologics (TNF inhibitors, IL-12/23 inhibitors, JAK inhibitors) act systemically — they affect immune function throughout the body. Entyvio is gut-selective: by blocking α4β7, it specifically prevents gut-homing T-cells from entering the intestinal mucosa, leaving systemic immune function largely intact. This translates to a more favorable safety profile (lower systemic infection risk, fewer immunosuppression-related complications) — at the cost of slower onset of action compared with some other biologics.
How Quickly Will Entyvio Work?
Entyvio typically takes longer to work than TNF inhibitors. Many patients begin to see improvement by week 6–14 of therapy; maximum benefit may take 6 months or longer. For patients with severe active disease, a faster-acting biologic (TNF inhibitor) may be preferred initially. For patients with moderate disease or those who prioritize the favorable safety profile, Entyvio is an excellent option.
Are There Drug Interactions I Should Know About?
Entyvio has minimal pharmacokinetic drug interactions because it is an antibody (no CYP450 metabolism). The main concern is live vaccines — avoid live vaccines while on Entyvio. Inactivated vaccines are fine. Tell your prescriber about all medications and supplements.
How Is Entyvio Different From Humira Or Remicade?
All three are IBD biologics with different mechanisms and routes. Entyvio (vedolizumab) — gut-selective integrin antagonist; IV every 8 weeks or SC every 2 weeks for maintenance; favorable systemic safety. Humira (adalimumab) — TNF inhibitor; SC every 2 weeks; many biosimilars at lower cost; faster onset, more systemic effects. Remicade (infliximab) — TNF inhibitor; IV every 8 weeks; biosimilars at lower cost; faster onset, more systemic effects. Choice depends on disease severity, prior treatments, comorbidities, and cost.
Can I Get Entyvio Through The PAP If I Have Medicare?
Yes. Medicare Part B (for IV infusions) or Medicare Part D (for SC formulation) beneficiaries can typically qualify. The manufacturer’s commercial copay savings program is reserved for commercially insured patients only — but the underlying PAP supports Medicare patients who meet income criteria.
What If My Application Is Denied?
If denied, we explore alternatives — switching to a TNF biosimilar (adalimumab or infliximab biosimilars at much lower cost), Stelara biosimilar, Skyrizi, Omvoh, or another IBD biologic with its own PAP, the manufacturer’s copay program for commercially insured patients, or independent foundations such as the Crohn’s & Colitis Foundation, PAN Foundation, or HealthWell Foundation. If we cannot find a path, you won’t be charged our service fee.
Take Control of Your Medication Costs
If you are struggling with the high cost of Entyvio, our team may be able to help you access assistance programs designed to make brand specialty IBD biologic therapy affordable. Check your eligibility today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.